QUANTITATIVE DETERMINATION OF SILYBIN IN CANINE PLASMA USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

Truong Giang Dang1, Ba Ngoc Minh Ho1, Hoang Hiep Nguyen1, Binh Duong Vu1, Nguyễn Thị Thảo2, Van Hien Pham1,
1 Trung tâm Nghiên cứu, Ứng dụng và Sản xuất thuốc, Học viện Quân y
2 Đơn nguyên Da liễu, Bệnh viện Đa khoa Hà Đông

Main Article Content

Abstract

Objectives: To develop and validate a high-performance liquid chromatography (HPLC) method for quantifying silybin (Si) in canine plasma. Methods: Chromatographic separation was carried out on a Luna C18 column using a gradient mobile phase of methanol:phosphoric acid:water (phase A, 20:0.5:80; phase B, 80:0.5:20). A 100µL injection volume was used. Plasma samples were prepared by precipitating proteins with methanol or perchloric acid. Catechin served as the internal standard. The method was validated according to FDA guidelines, assessing selectivity, specificity, system suitability, linearity, accuracy, precision, limits of detection (LOD) and quantification (LOQ), and sample stability. Results: Optimized sample preparation and chromatographic conditions were established. The method was selective and specific, with linear calibration ranges of 0.118 - 11.758 µg/mL for Si-A and 0.128 - 12.754 µg/mL for Si-B (R² = 0.9997). Relative standard deviations were not more than 3.99% and recoveries were between 85% and 115%. For Si-A, LOD and LOQ were 4.69 ng/mL and 14.20 ng/mL; for Si-B, they were 2.79 ng/mL and 8.46 ng/mL. Silybin concentrations remained stable after 24 hours (recoveries 98.30 - 114.43%) and after three freeze-thaw cycles (recoveries 85.34 - 111.65%). Conclusion: A HPLC method for the quantification of silybin in canine plasma was successfully developed and validated.

Article Details

References

1. Bijak M. Si, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.) - chemistry, bioavailability, and metabolism. Molecules. 2017; 22(11).
2. Pérez-Sánchez A, Cuyàs E, Ruiz-Torres V, et al. Intestinal permeability study of clinically relevant formulations of silibinin in Caco-2 cell monolayers. Int J Mol Sci. 2019; 20(7).
3. Chi C, Zhang C, Liu Y, et al. Phytosome-nanosuspensions for Si-phospholipid complex with increased bioavailability and hepatoprotection efficacy. Eur J Pharm Sci. 2020; 144: 105212.
4. Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a Si-phosphatidylcholine complex in dogs. J Vet Pharmacol Ther. 2007; 30(2): 132-138.
5. Marhol P, Bednář P, Kolářová P, et al. Pharmacokinetics of pure Si diastereoisomers and identification of their metabolites in rat plasma. 2015; 14:570-580.
6. FDA. Guidance for industry: Bioanalytical method validation, Services U.S.D.o.H.a.H., Administration F.a.D., USA. 2018.
7. Méndez-Sánchez N, Dibildox-Martinez M, Sosa-Noguera J, et al. Superior Si-Bioavailability of Si-phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers. BMC Pharmacol Toxicol. 2019; 20(1):5.